Global AI-driven Peptide Drug Discovery Platform Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our latest research, the global AI-driven Peptide Drug Discovery Platform market size will reach USD 1347 million in 2031, growing at a CAGR of 9.0% over the analysis period.
AI-driven Peptide Drug Discovery Platforms are tools that use artificial intelligence (AI) technology to accelerate and optimize the discovery and development process of peptide drugs. These platforms typically combine computational biology, machine learning, deep learning and other technologies to improve the efficiency of identifying, designing, optimizing and validating drug candidate molecules.
The global AI-driven peptide drug R&D market is in a period of rapid growth, with the core driving force coming from the high failure rate of traditional peptide R&D (over 90% elimination rate in the preclinical stage) and the significant advantages of AI technology in reducing costs and increasing efficiency (shortening the early R&D cycle by 50%). North America occupies a dominant position (about 48% market share in 2023), mainly due to the concentration of leading companies such as Insilico Medicine and Schrödinger and active biopharmaceutical venture capital; the Asia-Pacific region has the fastest growth rate (CAGR of 29%), thanks to China's "14th Five-Year Plan for Bioeconomic Development" policy support for AI pharmaceuticals and technological breakthroughs by local companies such as Tai Technology. In the sub-sectors, tumor treatment (PDC drug development) and anti-infective drugs (antimicrobial peptide optimization) account for more than 60% of the market share, while metabolic diseases and neurological diseases have become emerging growth poles due to breakthroughs in GLP-1 analogs and blood-brain barrier penetration technology. The challenges faced by the industry are the low clinical conversion rate (only 7% of AI-designed drug candidates enter Phase II clinical trials) and data barriers (data closure of pharmaceutical companies limits model training), but the deepening cooperation between multinational pharmaceutical companies and AI platforms (such as Pfizer and Cyclica jointly developing peptide vaccines) is promoting the openness of the ecosystem. In the future, peptide-nucleic acid conjugates (PepRNA) and AI-driven fully automated laboratories (such as the Strateos cloud-based robotics platform) may reshape the industry's competitive landscape.
This report is a detailed and comprehensive analysis for global AI-driven Peptide Drug Discovery Platform market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global AI-driven Peptide Drug Discovery Platform market size and forecasts, in consumption value ($ Million), 2020-2031
Global AI-driven Peptide Drug Discovery Platform market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global AI-driven Peptide Drug Discovery Platform market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global AI-driven Peptide Drug Discovery Platform market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for AI-driven Peptide Drug Discovery Platform
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global AI-driven Peptide Drug Discovery Platform market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Peptilogics, Pepticom Ltd, Menten AI, GUBRA, Creative Peptides, Exscalate, Generate Biomedicines, Receptor.AI, Insilico Medicine, Schrödinger, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
AI-driven Peptide Drug Discovery Platform market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Design and Generation Platform
Screening and Optimization Platform
Data-driven Platform
Others
Market segment by Application
Scientific Research
Pharmaceuticals
Market segment by players, this report covers
Peptilogics
Pepticom Ltd
Menten AI
GUBRA
Creative Peptides
Exscalate
Generate Biomedicines
Receptor.AI
Insilico Medicine
Schrödinger
BenevolentAI
Evotec
PeptiFinder
Xtalpi
Sun Novo
Zonsen Peplib Biotech
Tide Tron Biotech
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe AI-driven Peptide Drug Discovery Platform product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of AI-driven Peptide Drug Discovery Platform, with revenue, gross margin, and global market share of AI-driven Peptide Drug Discovery Platform from 2020 to 2025.
Chapter 3, the AI-driven Peptide Drug Discovery Platform competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and AI-driven Peptide Drug Discovery Platform market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of AI-driven Peptide Drug Discovery Platform.
Chapter 13, to describe AI-driven Peptide Drug Discovery Platform research findings and conclusion.
AI-driven Peptide Drug Discovery Platforms are tools that use artificial intelligence (AI) technology to accelerate and optimize the discovery and development process of peptide drugs. These platforms typically combine computational biology, machine learning, deep learning and other technologies to improve the efficiency of identifying, designing, optimizing and validating drug candidate molecules.
The global AI-driven peptide drug R&D market is in a period of rapid growth, with the core driving force coming from the high failure rate of traditional peptide R&D (over 90% elimination rate in the preclinical stage) and the significant advantages of AI technology in reducing costs and increasing efficiency (shortening the early R&D cycle by 50%). North America occupies a dominant position (about 48% market share in 2023), mainly due to the concentration of leading companies such as Insilico Medicine and Schrödinger and active biopharmaceutical venture capital; the Asia-Pacific region has the fastest growth rate (CAGR of 29%), thanks to China's "14th Five-Year Plan for Bioeconomic Development" policy support for AI pharmaceuticals and technological breakthroughs by local companies such as Tai Technology. In the sub-sectors, tumor treatment (PDC drug development) and anti-infective drugs (antimicrobial peptide optimization) account for more than 60% of the market share, while metabolic diseases and neurological diseases have become emerging growth poles due to breakthroughs in GLP-1 analogs and blood-brain barrier penetration technology. The challenges faced by the industry are the low clinical conversion rate (only 7% of AI-designed drug candidates enter Phase II clinical trials) and data barriers (data closure of pharmaceutical companies limits model training), but the deepening cooperation between multinational pharmaceutical companies and AI platforms (such as Pfizer and Cyclica jointly developing peptide vaccines) is promoting the openness of the ecosystem. In the future, peptide-nucleic acid conjugates (PepRNA) and AI-driven fully automated laboratories (such as the Strateos cloud-based robotics platform) may reshape the industry's competitive landscape.
This report is a detailed and comprehensive analysis for global AI-driven Peptide Drug Discovery Platform market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global AI-driven Peptide Drug Discovery Platform market size and forecasts, in consumption value ($ Million), 2020-2031
Global AI-driven Peptide Drug Discovery Platform market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global AI-driven Peptide Drug Discovery Platform market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global AI-driven Peptide Drug Discovery Platform market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for AI-driven Peptide Drug Discovery Platform
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global AI-driven Peptide Drug Discovery Platform market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Peptilogics, Pepticom Ltd, Menten AI, GUBRA, Creative Peptides, Exscalate, Generate Biomedicines, Receptor.AI, Insilico Medicine, Schrödinger, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
AI-driven Peptide Drug Discovery Platform market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Design and Generation Platform
Screening and Optimization Platform
Data-driven Platform
Others
Market segment by Application
Scientific Research
Pharmaceuticals
Market segment by players, this report covers
Peptilogics
Pepticom Ltd
Menten AI
GUBRA
Creative Peptides
Exscalate
Generate Biomedicines
Receptor.AI
Insilico Medicine
Schrödinger
BenevolentAI
Evotec
PeptiFinder
Xtalpi
Sun Novo
Zonsen Peplib Biotech
Tide Tron Biotech
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe AI-driven Peptide Drug Discovery Platform product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of AI-driven Peptide Drug Discovery Platform, with revenue, gross margin, and global market share of AI-driven Peptide Drug Discovery Platform from 2020 to 2025.
Chapter 3, the AI-driven Peptide Drug Discovery Platform competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and AI-driven Peptide Drug Discovery Platform market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of AI-driven Peptide Drug Discovery Platform.
Chapter 13, to describe AI-driven Peptide Drug Discovery Platform research findings and conclusion.
Table of Contents
126 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
